Takeda Pharmaceutical (TAK) Projected to Release Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to be announcing its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect Takeda Pharmaceutical to announce earnings of $0.1689 per share and revenue of $7.1469 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. The firm had revenue of $6.90 billion during the quarter. On average, analysts expect Takeda Pharmaceutical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $16.86 on Thursday. The company’s 50 day moving average price is $16.16 and its two-hundred day moving average price is $17.01. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The firm has a market cap of $54.00 billion, a PE ratio of 43.22 and a beta of -0.07. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59.

Wall Street Analyst Weigh In

TAK has been the subject of several recent research reports. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the company. Compound Planning Inc. boosted its position in shares of Takeda Pharmaceutical by 8.3% during the 4th quarter. Compound Planning Inc. now owns 45,673 shares of the company’s stock worth $712,000 after acquiring an additional 3,515 shares in the last quarter. Summit Global Investments increased its stake in Takeda Pharmaceutical by 22.5% in the fourth quarter. Summit Global Investments now owns 104,373 shares of the company’s stock valued at $1,627,000 after acquiring an additional 19,171 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $360,000. XTX Topco Ltd raised its position in Takeda Pharmaceutical by 437.7% during the fourth quarter. XTX Topco Ltd now owns 71,476 shares of the company’s stock valued at $1,114,000 after purchasing an additional 58,183 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its stake in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after purchasing an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.